KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Notes Payables (2023 - 2025)

Bionano Genomics (BNGO) has disclosed Notes Payables for 3 consecutive years, with $10.0 million as the latest value for Q4 2025.

  • Quarterly Notes Payables fell 50.99% to $10.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.0 million through Dec 2025, down 50.99% year-over-year, with the annual reading at $10.0 million for FY2025, 50.99% down from the prior year.
  • Notes Payables hit $10.0 million in Q4 2025 for Bionano Genomics, up from $9.8 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $69.8 million in Q4 2023 to a low of $9.8 million in Q3 2025.
  • Historically, Notes Payables has averaged $22.0 million across 3 years, with a median of $15.0 million in 2024.
  • Biggest five-year swings in Notes Payables: plummeted 70.83% in 2024 and later plummeted 34.29% in 2025.
  • Year by year, Notes Payables stood at $69.8 million in 2023, then tumbled by 70.83% to $20.4 million in 2024, then crashed by 50.99% to $10.0 million in 2025.
  • Business Quant data shows Notes Payables for BNGO at $10.0 million in Q4 2025, $9.8 million in Q3 2025, and $11.8 million in Q2 2025.